Key result
Administration of 4 mg/kg Withaferin-A daily for 2 weeks reduced isoproterenol-induced myocardial fibrosis by 50% in mice.
Why the study?
Does Withaferin-A reduce type I collagen expression and prevent myocardial fibrosis in preclinical models?
Population
In vitro: lung, skin and heart fibroblasts, primary hepatic stellate cells. In vivo: mice with…
Design
Preclinical
Follow-up
2 weeks (in vivo)
Authors
Loading...
Should not change clinical practice; leaves open translation of Withaferin-A to human cardiac fibrosis.
Does Withaferin-A reduce type I collagen expression and prevent myocardial fibrosis in preclinical models?
Effect estimate: 50% reduction
Withaferin-A exhibits significant anti-fibrotic properties in vitro and reduces isoproterenol-induced myocardial fibrosis by 50% in vivo, suggesting potential as a therapeutic agent for fibroproliferative diseases.
Challa et al. (2012) studied Myocardial fibrosis (n=24). Withaferin-A vs. Vehicle was evaluated on Isoproterenol-induced myocardial fibrosis (50% reduction). Administration of 4 mg/kg Withaferin-A daily for 2 weeks reduced isoproterenol-induced myocardial fibrosis by 50% in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: